Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer

Seeking AlphaJan 4 00:21

Gilead (GILD.US) has received approval for the long-acting HIV treatment "Lenacapavir" to be marketed in China.

The NMPA official website shows that Gilead (GILD.US) has received approval for the marketing application of its HIV therapy lenacapavir tablets and lenacapavir injection.

Zhitong FinanceJan 2 21:30

After experiencing a bumper harvest in 2024, the USA ETF may encounter setbacks this year.

The USA Exchange Traded Fund (ETF) received a record inflow of $1.1 trillion in 2024, but entering 2025, rapid growth may face more obstacles.

Zhitong FinanceJan 2 20:49

Express News | The HIV long-acting therapy Lenacapavir, which is administered twice a year, has been approved in China.

BreakingsJan 2 17:54

Express News | Gilead's long-acting HIV therapy has been approved for sale in China, requiring administration only twice a year.

BreakingsJan 2 16:49

Is Gilead Sciences, Inc. (GILD) the Best Pharma Dividend Stocks to Buy In 2024?

Yahoo FinanceDec 31, 2024 05:01